What question did this study set out to answer?

Investigate whether SIRT3 activation by honokiol prevents doxorubicin-induced cardiotoxicity and mitochondrial damage without compromising chemotherapy efficacy.

March 11, 2017OncotargetOpen Access

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

View Full Paper

Ask AI

Bookmark

Why the study?

Does honokiol prevent doxorubicin-induced cardiotoxicity in preclinical models?

Population

Rat neonatal cardiomyocytes and mice (including mice bearing prostate tumor-xenografts) exposed to doxorubicin

Comparison

Honokiol (HKL) vs Doxorubicin alone

Design

Preclinical

Authors

VPVinodkumar B. PillaiUniversity of Chicago AKAbhinav KanwalCentral University of Punjab YFYong Hu FangJinan Maternity And Care Hospital

Discussion

Member takes

Implication

Hypothesis-generating for honokiol in doxorubicin cardiotoxicity; leaves open translation to patients and requires clinical trials.

Key Points

Investigate whether SIRT3 activation by honokiol prevents doxorubicin-induced cardiotoxicity and mitochondrial damage without compromising chemotherapy efficacy.
Assessed reactive oxygen species production, mitochondrial fragmentation, and cell death in doxorubicin-exposed rat neonatal cardiomyocytes treated with honokiol.
Evaluated cardiac toxicity, mitochondrial DNA damage, and mitochondrial function in mice treated with doxorubicin and honokiol.
Tested antitumor activity and cardiotoxicity of combination honokiol and doxorubicin treatment in prostate tumor-xenograft mouse models.
Honokiol-mediated SIRT3 activation prevented doxorubicin-induced ROS generation, mitochondrial fragmentation, and cell death in vitro while promoting mitochondrial fusion.
Honokiol administration in mice prevented doxorubicin-induced cardiac toxicity by reducing mitochondrial DNA damage and restoring mitochondrial function.
Co-treatment with honokiol and doxorubicin maintained prostate tumor growth inhibition while significantly reducing cardiac toxicity in xenograft mice.

Structured PICO

Does honokiol prevent doxorubicin-induced cardiotoxicity in preclinical models?

Population

Rat neonatal cardiomyocytes and mice (including mice bearing prostate tumor-xenografts) exposed to doxorubicin

Intervention

Honokiol (HKL)

Comparator

Doxorubicin alone

Outcome

Doxorubicin-induced cardiotoxicity (mitochondrial damage, ROS production, cell death, and cardiac toxicity)surrogate

Honokiol, a SIRT3 activator, protects against doxorubicin-induced cardiotoxicity in preclinical models without compromising its anti-tumor efficacy.

Cite This Study

Pillai et al. (2017) studied this question.

synapsesocial.com/papers/69d572e075589c71d767e8a4 https://doi.org/10.18632/oncotarget.16133

Topics

Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider